lintuzumab
seagen
['lintuzumab', 'leukemia', 'myeloid', 'leusm']
lintuzumab-ac225 + salvage chemotherapy showed potential benefit through the elimination of residual leukemia cells &amp; a tolerable safety profile in patients with relapsed/refractory acute myeloid leukemia. #ash22 #leusm | 
Oncology news and insights from leading researchers and cancer centers.